CN103622933B - Cefdinir capsule and preparation method thereof - Google Patents
Cefdinir capsule and preparation method thereof Download PDFInfo
- Publication number
- CN103622933B CN103622933B CN201310700859.9A CN201310700859A CN103622933B CN 103622933 B CN103622933 B CN 103622933B CN 201310700859 A CN201310700859 A CN 201310700859A CN 103622933 B CN103622933 B CN 103622933B
- Authority
- CN
- China
- Prior art keywords
- cefdinir
- capsule
- crystal formation
- consumption
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
The invention relates to a cefdinir capsule and a preparation method thereof, belonging to the technical field of pharmaceutical preparations. The cefdinir capsule contains 80-120 parts by weight of cefdinir crystal form, 6-10 parts by weight of aerosil and 2-6 parts by weight of sodium carboxymethyl starch, wherein the X-ray powder diffraction pattern of the cefdinir crystal form has characteristic absorption peaks at reflection angles 2theta of 12.1+/-0.2 degrees, 17.5+/-0.2 degrees, 19.6+/-0.2 degrees, 21.4+/-0.2 degrees, 24.7+/-0.2 degrees, 29.5+/-0.2 degrees and 31.8+/-0.2 degrees. As the cefdinir crystal form is used by the cefdinir capsule, absorption of the cefdinir capsule in human bodies is accelerated and the bioavailability is improved, thus the curative effects are improved. The cefdinir capsule has better stability and dissolution effect, improves the use efficiency of unit dose and has high economic and social meanings.
Description
Technical field
The present invention relates to a kind of capsule for medicine and preparation method thereof, particularly relate to a kind of Cefdinir capsule and preparation method thereof, belong to technical field of medicine.
Background technology
Since the seventies, cephalosporin entered Chinese market, the advantage such as strong with antibacterial action, clinical efficacy is high, toxicity is low, anaphylaxis is few is used widely clinical.But through Clinical practice for many years, antibacterial has produced general drug resistance to first generation cephalosporin, to the drug resistance of second generation cephalosporin also in continuous rising.The cephalosporin of exigence a new generation replaces existing kind clinically.So just concentrate on third and fourth peroral dosage form cephalosporin the focus of cephalo-type drug research in recent years in generation.And the existence that the disease such as such as tonsillitis, sinusitis, otitis media, acute bronchitis, pneumonia, abdominal cavity, urogenital infections is general in the whole world in recent years, although there had multiple cephalosporins medicine to be applied to be clinical, but the demand of medicine is still sharply being increased, is making its quantity be difficult to satisfy the demand.Therefore, the antibiotics of development of new and preparation tool are of great significance.
Third generation Cephalosporins medicine cefdinir on the basis of cefixime, carries out structure of modification obtain.Compensate for the shortcoming that original third generation cephalosporin is weak to gram positive bacteria effect, become a broad ectrum antibiotic truly.Be characterized in having enough antibacterial abilities in the first stage for the treatment of and to avoid the generation of drug resistance.Strict checking U.S. FDA through for many years announces the skin structure infections that cefdinir can act on community acquired pneumonia, chronic bronchitis, acute upper jaw sinusitis, pharyngitis, tonsillitis and some non-complexes caused by staphylococcus aureus, streptococcus pneumoniae, streptococcus pyogenes, hemophilus influenza and cattamolar's bacteria safely and effectively.
Cefdinir has very high stability to beta-lactamase, from relative degradation rate numerical value, lower than first and second cephalo Representative Cultivars---cefalexin and Cefaclor 1 ~ 2 order of magnitude in generation.This today be on the rise at clinical bacteria drug resistance has more realistic meaning.This advantage is relevant with toxin associated proteins combination rate height blue or green on cefdinir and bacteria cell wall in a word, and cephalosporin kind is higher in conjunction with the ratio of onset with pathogenic bacterium than ever to mean cefdinir.Cefdinir is as the minimum antibiotic of current taking dose, identical with the old kind effect exceeding its a few multiple dose, even has higher cure rate.
As a kind of antibacterials of a new generation, cefdinir has that taking dose is little, has a broad antifungal spectrum, antibacterial activity are strong, drug resistance is low, safety is high, action effect is fast, cure rate advantages of higher, therefore for the Disease suffering from some inflammation, cefdinir is a medicine very likely.Cefdinir production added value is high, also man of administration manufacturer is brought considerable economic benefit.
Research in recent years shows, increases sharply to the bacterial isolates of Multiple Classes of Antibiotics drug resistance, and the mankind must accelerate to develop new antibiotic to defeat infectious disease.The listing of cefdinir, for clinicist increases a kind of new medicine for the treatment of multi-infection.In order to adapt to clinical needs, alleviate the medication burden of patient, improve health status and the quality of life of patient, therefore, from safety, effectively, the angle of economy and market in urgent need, develop Third generation Cephalosporins medicine cefdinir and preparation tool is of great significance.At present, the Cefdinir capsule kind that market uses is more, and there is some difference for the drug quality of different manufacturers, brings certain difficulty to selection of clinical.
Summary of the invention
Technical problem to be solved by this invention is that the defect overcoming prior art provides a kind of Cefdinir capsule, and this capsule has that stability is strong, dissolution high, for Hospital Drugs preferentially and the product that provides of clinical application.In addition, the present invention further provides the preparation method of this capsule.
Technical problem of the present invention is realized by following technical scheme.
A kind of Cefdinir capsule, cefdinir crystal formation containing 80 ~ 120 weight portions in this capsule, the micropowder silica gel of 6 ~ 10 weight portions, the carboxymethyl starch sodium of 2 ~ 6 weight portions, wherein, its X-ray powder diffraction pattern of described cefdinir crystal formation is 12.1 ± 0.2 ° at angle of reflection 2 θ, 17.5 ± 0.2 °, 19.6 ± 0.2 °, 21.4 ± 0.2 °, 24.7 ± 0.2 °, 29.5 ± 0.2 °, there is characteristic absorption peak at 31.8 ± 0.2 ° of places.
Above-mentioned Cefdinir capsule, the means of differential scanning calorimetry endothermic peak of described cefdinir crystal formation is respectively at 91.78 DEG C ± 3 DEG C, 142.21 DEG C ± 3 DEG C, 237.24 DEG C ± 3 DEG C.
Above-mentioned Cefdinir capsule, the infrared absorption spectroscopy of described cefdinir crystal formation is at 3413cm
-1, 2991cm
-1, 2936cm
-1, 2367cm
-1, 1573cm
-1, 1445cm
-1, 1023cm
-1, 645cm
-1place has characteristic absorption peak.
Prepare a method for above-mentioned Cefdinir capsule, comprise the steps:
A. prepare cefdinir crystal formation: cefdinir is dissolved in methyl iso-butyl ketone (MIBK) and is warmed to 55 ~ 60 DEG C, the consumption of described cefdinir is 1: 10 ~ 20 with the weight g of methyl iso-butyl ketone (MIBK) consumption, volume ml ratio; Behind hydrochloric acid solution adjust pH to 3.0 ~ 5.0 of 30%, in 5 minutes, add normal octane, the consumption of described normal octane and the volume ratio of methyl iso-butyl ketone (MIBK) consumption are 0.03 ~ 0.07: 1; Kept 20 minutes at 55 ~ 60 DEG C by solution, add methyl tertiary butyl ether(MTBE) and be cooled to-10 ~-15 DEG C of crystallizes, the consumption of described methyl tertiary butyl ether(MTBE) and the volume ratio of methyl iso-butyl ketone (MIBK) consumption are 5 ~ 9: 1; Filter, 55 ~ 60 DEG C of dryings, obtain cefdinir crystal formation;
B. get the raw materials ready: take each supplementary material by recipe quantity, wherein cefdinir crystal formation raw material and carboxymethyl starch sodium cross 60 mesh sieves respectively;
C. mix: by micropowder silica gel, carboxymethyl starch sodium mixing, first add the raw material mixing of half amount, then add remaining raw material mix homogeneously;
D. fill: be filled in capsule, polishing, packaging.
The invention provides a kind of Cefdinir capsule being different from prior art, the cefdinir crystal formation impurity in this capsule is few, and purity is high, can reach more than 99.8%, and particle diameter is large compared with little, specific surface area, good fluidity, stability are high; Under simulation listing terms of packing, place under temperature 40 DEG C ± 2 DEG C, relative humidity are 75% ± 5% condition after 6 months, every quality detecting index is without significant change, illustrate that the crystal formation of this crystal formation bibliographical information than ever has better quality stability and stability of crystal form, illustrate further Cefdinir capsule of the present invention to be more conducive to ensureing the efficacy and saferry of its pharmaceutical preparation in clinical practice, be more suitable for using as crude drug.In addition, Cefdinir capsule of the present invention accelerates the absorption in human body owing to using cefdinir crystal formation, improves bioavailability, thus improves curative effect; Stable better, result of extraction is better, improves the service efficiency of unit dose, for Hospital Drugs preferentially and the selection that provides of clinical application, there is very high economy and social meaning.
Accompanying drawing explanation
The diffracting spectrum of the powder X-ray line diffraction of Fig. 1 cefdinir crystal formation of the present invention.
The powder thermogravimetric analysis collection of illustrative plates of Fig. 2 cefdinir crystal formation of the present invention.
The powder infrared spectrum collection of illustrative plates of Fig. 3 cefdinir crystal formation of the present invention.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is described in further details.
Embodiment 1 prepares Cefdinir capsule
Prescription:
Preparation method:
A. cefdinir crystal formation is prepared: 200g cefdinir is dissolved in 3000ml methyl iso-butyl ketone (MIBK) and is warmed to 57 DEG C, after the hydrochloric acid solution adjust pH to 4.0 of 30%, 150ml normal octane is added in 5 minutes, solution is kept 20 minutes at 57 DEG C, adds 21000ml methyl tertiary butyl ether(MTBE) and be cooled to-13 DEG C of crystallizes, filter, 57 DEG C of dryings, obtain 193.8g cefdinir crystal formation, it is 99.86% that yield 96.9%, HPLC measures purity;
B. get the raw materials ready: take each supplementary material by recipe quantity, wherein cefdinir crystal formation raw material and carboxymethyl starch sodium cross 60 mesh sieves respectively;
C. mix: by micropowder silica gel, carboxymethyl starch sodium mixing, first add spore ground Buddhist nun's crystal formation raw material mixing of half amount, then add remaining cefdinir crystal formation raw material mix homogeneously;
D. fill: be filled in capsule, polishing, packaging.
Data monitoring:
The diffracting spectrum of the powder X-ray line diffraction of gained cefdinir crystal formation is as Fig. 1.
The powder thermogravimetric analysis collection of illustrative plates of gained cefdinir crystal formation is as Fig. 2.
The powder infrared spectrum collection of illustrative plates of gained cefdinir crystal formation is as Fig. 3.
Embodiment 2 prepares Cefdinir capsule
Prescription:
Preparation method:
A. cefdinir crystal formation is prepared: 100g cefdinir is dissolved in 1000ml methyl iso-butyl ketone (MIBK) and is warmed to 55 DEG C, after the hydrochloric acid solution adjust pH to 3.0 of 30%, 30ml normal octane is added in 5 minutes, solution is kept 20 minutes at 55 DEG C, adds 5000ml methyl tertiary butyl ether(MTBE) and be cooled to-10 DEG C of crystallizes, filter, 55 DEG C of dryings, obtain 95.4g cefdinir crystal formation, it is 99.39% that yield 95.4%, HPLC measures purity;
B. get the raw materials ready: take each supplementary material by recipe quantity, wherein cefdinir crystal formation raw material and carboxymethyl starch sodium cross 60 mesh sieves respectively;
C. mix: by micropowder silica gel, carboxymethyl starch sodium mixing, first add spore ground Buddhist nun's crystal formation raw material mixing of half amount, then add remaining cefdinir crystal formation raw material mix homogeneously;
D. fill: be filled in capsule, polishing, packaging.
Embodiment 3 prepares Cefdinir capsule
Prescription:
Preparation method:
A. cefdinir crystal formation is prepared: 150g cefdinir is dissolved in 3000ml methyl iso-butyl ketone (MIBK) and is warmed to 60 DEG C, after the hydrochloric acid solution adjust pH to 5.0 of 30%, 210ml normal octane is added in 5 minutes, solution is kept 20 minutes at 60 DEG C, adds 27000ml methyl tertiary butyl ether(MTBE) and be cooled to-15 DEG C of crystallizes, filter, 60 DEG C of dryings, obtain 144.1g cefdinir crystal formation, it is 99.53% that yield 96.1%, HPLC measures purity;
B. get the raw materials ready: take each supplementary material by recipe quantity, wherein cefdinir crystal formation raw material and carboxymethyl starch sodium cross 60 mesh sieves respectively;
C. mix: by micropowder silica gel, carboxymethyl starch sodium mixing, first add spore ground Buddhist nun's crystal formation raw material mixing of half amount, then add remaining cefdinir crystal formation raw material mix homogeneously;
D. fill: be filled in capsule, polishing, packaging.
Comparative example 1 prepares Cefdinir capsule
Prescription:
Preparation method:
A. get the raw materials ready: take each supplementary material by recipe quantity, wherein cefdinir raw material and carboxymethyl starch sodium cross 60 mesh sieves respectively;
B. mix: by micropowder silica gel, magnesium stearate, carboxymethyl starch sodium mixing, first add spore ground Buddhist nun's raw material mixing of half amount, then add remaining cefdinir raw material mix homogeneously;
C. fill: be filled in capsule, polishing, packaging.
The study on the stability contrast test of comparative experimental example 1 cefdinir crystal formation of the present invention
Get the commercially available cefdinir raw material used in comparative example 1 as a comparison sample.
According to (Chinese Pharmacopoeia version in 2010 two annex XIX C) relevant regulations, accelerated test is carried out to cefdinir crystal formation of the present invention and comparative sample.Get each embodiment 1 ~ 3 respectively and comparative sample appropriate, simulation listing packaging, place 6 months under temperature 40 DEG C ± 2 DEG C, relative humidity are 75% ± 5% condition, sample respectively respectively at the 0th, 1,2,3,6 the end of month, measure and record sample property, clarity of solution, loss on drying, related substance, content equistability inspection target, concrete data see the following form 1:
The accelerated test result table of table 1 embodiment 1 ~ 3 and comparative sample
Above result of the test shows: under simulation listing terms of packing, embodiment 1 ~ 3 and comparative sample are placed after 6 months under temperature 40 DEG C ± 2 DEG C, relative humidity are 75% ± 5% condition, every Testing index has no significant change, all in prescribed limit, illustrate that above-mentioned sample all has good stability.But embodiment 1 ~ 3 sample places the related substance after 6 months relative to comparative sample and changes of contents amplitude is less, illustrates in stability, and cefdinir crystal formation of the present invention advantageously.In addition, also can find out from upper table data, the related substance (comprising single maximum contaminant and total impurities) of cefdinir crystal formation of the present invention is lower than comparative sample, content is then higher than comparative sample, illustrate that cefdinir crystal formation impurity content of the present invention is less, purity is higher, more can ensure the efficacy and saferry of its pharmaceutical preparation in clinical practice.
The mobility of comparative experimental example 2 cefdinir crystal formation of the present invention compares
Angle of repose is the easiest method checking powder fluidity quality, and angle of repose is less, illustrates that frictional force is less, and mobility is better.This test adopts injection method (fixed funnel method) to measure in embodiment 1 ~ 3 and comparative example 1 angle of repose of the commercially available cefdinir raw material used.Pour testing sample into funnel, make it fall into disc centre lightly, equably, form a cone, when material is reinforced along stopping when freely falling disk border from powder body hypotenuse, measure angle of repose with protractor, measurement result is in table 2.
Measurement result angle of repose of table 2 cefdinir crystal formation
| Sample | Outward appearance | Angle of repose |
| Embodiment 1 | White crystalline powder | 29.0 |
| Embodiment 2 | White crystalline powder | 32.5 |
| Embodiment 3 | White crystalline powder | 34.8 |
| Comparative example 1 | White crystalline adhesion powder | 44.6 |
Can be found out by the result of the test of upper table 2: embodiment 1 ~ 3, also be cefdinir crystal formation of the present invention, the angle of repose of its crystal particle is less than 35 degree, shows good fluidity, the need for liquidity in production process can be met, be applicable to being applied to production pharmaceutical preparation and storage transport; And the angle of repose of the commercially available cefdinir raw material that comparative example 1 uses is greater than 40 degree, mobility is poor, cannot meet Production requirement, not be suitable for useful in preparing drug formulations; Therefore cefdinir crystal formation of the present invention is compared with commercially available cefdinir raw material, its mobility of particle is better, more can meet Production requirement.
Content uniformity, the dissolution of comparative experimental example 3 Cefdinir capsule of the present invention, the results are shown in Table 3.
The Cefdinir capsule measurement result of table 3 embodiment 1 ~ 3, comparative example 1
| Sample number into spectrum | Content uniformity | Dissolution |
| Embodiment 1 | -2.5～3.3％ | 93.3％ |
| Embodiment 2 | -2.6～3.5％ | 95.0％ |
| Embodiment 3 | -2.9～3.5％ | 94.8％ |
| Comparative example 1 | -5.9～5.5％ | 85.5％ |
As can be seen from Table 3,90% is greater than by the Cefdinir capsule dissolution of the present invention of embodiment 1,2,3 formula preparation, content uniformity is less than ± and 5.0%, obviously be better than other comparative examples, illustrate that Cefdinir capsule quality of the present invention is more controlled, more can ensure the safe and effective of Clinical practice.
The Buddhist nun's capsule stability test of comparative experimental example 4 spore ground of the present invention
According to the stability testing method of Chinese Pharmacopoeia version in 2010 two annex, respectively accelerated test and long-term stable experiment are carried out to the Cefdinir capsule obtained by embodiment 1 ~ 3, comparative example 1, accelerated test investigates 6 months under temperature 40 DEG C ± 2 DEG C, relative humidity are 75% ± 5% condition, long term test investigates 24 months under temperature 25 ± 2 DEG C, relative humidity are 60 ± 5% conditions, the results are shown in Table 4:
Table 4 Cefdinir capsule stability experiment result
As can be seen from Table 8,6 months are investigated by the Cefdinir capsule accelerated test of the present invention of embodiment 4 formula preparation, long term test investigates 36 months, Key Quality Indicator character, dissolution, related substance, content have no significant change, highly stable, and the amplitude of variation of indices is starkly lower than other comparative example preparations, show that Cefdinir capsule quality of the present invention is more stablized controlled, Clinical practice is safer and more effective.
Above-described embodiment is only for illustrating technical conceive of the present invention and advantage; the present invention also can have other variation; as well known to the skilled person; above-described embodiment only plays the exemplary role in foregoing invention protection domain; for those of ordinary skills; in the protection domain that the present invention limits, also have a lot of conventional deformation and other embodiment, these distortion and embodiment are all by within the protection domain that awaits the reply in the present invention.
Claims (4)
1. a Cefdinir capsule, it is characterized in that, cefdinir crystal formation containing 80 ~ 120 weight portions in this capsule, the micropowder silica gel of 6 ~ 10 weight portions, the carboxymethyl starch sodium of 2 ~ 6 weight portions, wherein, its X-ray powder diffraction pattern of described cefdinir crystal formation is 12.1 ± 0.2 ° at angle of reflection 2 θ, 17.5 ± 0.2 °, 19.6 ± 0.2 °, 21.4 ± 0.2 °, 24.7 ± 0.2 °, 29.5 ± 0.2 °, there is characteristic absorption peak at 31.8 ± 0.2 ° of places.
2. Cefdinir capsule according to claim 1, is characterized in that, the means of differential scanning calorimetry endothermic peak of described cefdinir crystal formation is respectively at 91.78 DEG C ± 3 DEG C, 142.21 DEG C ± 3 DEG C, 237.24 DEG C ± 3 DEG C.
3. Cefdinir capsule according to claim 2, is characterized in that, the infrared absorption spectroscopy of described cefdinir crystal formation is at 3413cm
-1, 2991cm
-1, 2936cm
-1, 2367cm
-1, 1573cm
-1, 1445cm
-1, 1023cm
-1, 645cm
-1place has characteristic absorption peak.
4. prepare a method for the Cefdinir capsule as described in claim as arbitrary in claims 1 to 3, it is characterized in that, comprise the steps:
A. prepare cefdinir crystal formation: cefdinir is dissolved in methyl iso-butyl ketone (MIBK) and is warmed to 55 ~ 60 DEG C, the consumption of described cefdinir is 1: 10 ~ 20 with the weight g of methyl iso-butyl ketone (MIBK) consumption, volume ml ratio; Behind hydrochloric acid solution adjust pH to 3.0 ~ 5.0 of 30%, in 5 minutes, add normal octane, the consumption of described normal octane and the volume ratio of methyl iso-butyl ketone (MIBK) consumption are 0.03 ~ 0.07: 1; Kept 20 minutes at 55 ~ 60 DEG C by solution, add methyl tertiary butyl ether(MTBE) and be cooled to-10 ~-15 DEG C of crystallizes, the consumption of described methyl tertiary butyl ether(MTBE) and the volume ratio of methyl iso-butyl ketone (MIBK) consumption are 5 ~ 9: 1; Filter, 55 ~ 60 DEG C of dryings, obtain cefdinir crystal formation;
B. get the raw materials ready: take each supplementary material by recipe quantity, wherein cefdinir crystal formation raw material and carboxymethyl starch sodium cross 60 mesh sieves respectively;
C. mix: by micropowder silica gel, carboxymethyl starch sodium mixing, first add the raw material mixing of half amount, then add remaining raw material mix homogeneously;
D. fill: be filled in capsule, polishing, packaging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310700859.9A CN103622933B (en) | 2013-12-19 | 2013-12-19 | Cefdinir capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310700859.9A CN103622933B (en) | 2013-12-19 | 2013-12-19 | Cefdinir capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103622933A CN103622933A (en) | 2014-03-12 |
| CN103622933B true CN103622933B (en) | 2015-04-08 |
Family
ID=50204622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310700859.9A Active CN103622933B (en) | 2013-12-19 | 2013-12-19 | Cefdinir capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103622933B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104473901B (en) * | 2014-12-26 | 2017-02-22 | 石药集团中诺药业（石家庄）有限公司 | Cefdinir capsule and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935507A (en) * | 1987-08-19 | 1990-06-19 | Fujisawa Pharmaceutical Co., Ltd. | Crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) |
| WO2006117794A1 (en) * | 2005-05-02 | 2006-11-09 | Hetero Drugs Limited | A novel crystalline form of cefdinir |
| CN102266306A (en) * | 2011-07-13 | 2011-12-07 | 石家庄四药有限公司 | Cefdinir capsules and preparation method thereof |
| CN102935075A (en) * | 2012-11-22 | 2013-02-20 | 海南三叶美好制药有限公司 | Cefdinir capsule and preparation method thereof |
| CN103263398A (en) * | 2013-06-06 | 2013-08-28 | 山东罗欣药业股份有限公司 | Cefdinir composition capsule and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050137182A1 (en) * | 2003-06-02 | 2005-06-23 | Ramesh Dandala | Novel crystalline form of cefdinir |
-
2013
- 2013-12-19 CN CN201310700859.9A patent/CN103622933B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935507A (en) * | 1987-08-19 | 1990-06-19 | Fujisawa Pharmaceutical Co., Ltd. | Crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) |
| WO2006117794A1 (en) * | 2005-05-02 | 2006-11-09 | Hetero Drugs Limited | A novel crystalline form of cefdinir |
| CN102266306A (en) * | 2011-07-13 | 2011-12-07 | 石家庄四药有限公司 | Cefdinir capsules and preparation method thereof |
| CN102935075A (en) * | 2012-11-22 | 2013-02-20 | 海南三叶美好制药有限公司 | Cefdinir capsule and preparation method thereof |
| CN103263398A (en) * | 2013-06-06 | 2013-08-28 | 山东罗欣药业股份有限公司 | Cefdinir composition capsule and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 头孢地尼胶囊的处方工艺研究;康帅;《河北工业科技》;20120731;第29卷(第4期);第208-210页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103622933A (en) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101856356B (en) | Cefazedone sodium composition powder injection | |
| CN105434373A (en) | Oxiracetam freeze-drying preparation for injection and preparation method thereof | |
| CN104788470A (en) | Cefetamet pivoxil hydrochloride compound for treating sensitive bacteria infectious diseases | |
| CN103622916B (en) | Cefixime dry suspension and preparation method thereof | |
| CN103622933B (en) | Cefdinir capsule and preparation method thereof | |
| CN103467494B (en) | Novel crystal form of cefdinir and preparation method thereof | |
| CN103446075A (en) | Cefaclor capsule and preparation method thereof | |
| CN103330685A (en) | Cefaclor granule and preparation method thereof | |
| CN102327270B (en) | Beta-lactam compound antibiotic composition | |
| CN104688713A (en) | Cefradine capsule and preparation method thereof | |
| CN102755325B (en) | Cefoxitin sodium medicinal composition, powder injection and preparation method thereof | |
| CN103637992B (en) | Cefdinir granular preparation and preparation method thereof | |
| CN103520120B (en) | A kind of L-084 composition granule | |
| CN103893132B (en) | A kind of cefdinir granules and preparation technology thereof | |
| CN102936254B (en) | Drug composition containing ceftizoxime sodium compound | |
| CN105496984B (en) | A kind of Cefixime Capsules and preparation method thereof that quality is stable | |
| CN104382849B (en) | A kind of cefaclor dry suspension and preparation method thereof | |
| CN103230367B (en) | Cefpodoxime proxetil composition dry suspension and preparation method thereof | |
| CN100508982C (en) | Medicinal composition containing ceftriaxone sodium and lidocaine hydrochloride injection | |
| CN104844624B (en) | A kind of cefoperazone sodium sulbactam sodium eutectic and composition and method of making the same | |
| CN106310286B (en) | Tosufloxacin tosylate composition | |
| CN104473889A (en) | Cefaclor dispersible tablet and preparation method thereof | |
| CN103127114B (en) | Medicinal composition including piperacillin sodium and sulbactam sodium | |
| CN103304604B (en) | Clindamycin phosphate compound and preparation method and pharmaceutical composition thereof | |
| CN105193736A (en) | Medicinal cefetamet pivoxil hydrochloride dry suspension for treating sensitive bacterial infection diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |